EGFR and Skin rash: This meta-analysis did demonstrate that EGFR-targeted therapy was associated with an increased risk of treatment-related death (pooled odds ratio (OR) 5.18, 95% CI 1.58–16.97 p = 0.0007) (10 treatment-related deaths out of 3718 patients included in meta-analysis) and toxicities including grade 3–4 rash (OR 4.82 95% CI 1.18–19.69 p = 0.03) and a near significant increase in grade 3–4 diarrhoea (OR 1.75, 95% CI 0.97–3.15, p = 0.25).